{"description":"Ocular AEs were collected per participant, not per eye. Hematologic toxicity was collected if it was a reason for change to treatment. No other AEs were collected. Ocular toxicity was collected systematically through optometrist visits; measured per the Keratopathy Visual Acuity scale, using belantamab mafodotin REMS guidelines. Ocular symptoms were reported ad hoc by patients at individual clinic visits, as a non-systematic assessment. Serious AEs were not monitored/assessed.","eventGroups":[{"deathsNumAffected":10,"deathsNumAtRisk":30,"description":"Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023.","id":"EG000","otherNumAffected":29,"otherNumAtRisk":30,"seriousNumAffected":0,"seriousNumAtRisk":0,"title":"Multiple Myeloma/Blenrep Participants"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Ocular adverse events were collected per participant, not per eye.","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v. 25.1","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":30,"numEvents":320}],"term":"Keratopathy"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Ocular adverse events were collected per participant, not per eye.","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v. 25.1","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30,"numEvents":3}],"term":"Corneal epithelium defect"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Ocular adverse events were collected per participant, not per eye.","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v. 25.1","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":30,"numEvents":244}],"term":"Visual acuity reduced"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Ocular adverse events were collected per participant, not per eye.","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v. 25.1","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":30,"numEvents":102}],"term":"Blurred vision"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Ocular adverse events were collected per participant, not per eye.","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v. 25.1","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":30,"numEvents":32}],"term":"Dry eye"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Ocular adverse events were collected per participant, not per eye.","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v. 25.1","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":30,"numEvents":26}],"term":"Photophobia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Ocular adverse events were collected per participant, not per eye.","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v. 25.1","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":30,"numEvents":6}],"term":"Foreign body sensation in the eye"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Ocular adverse events were collected per participant, not per eye.","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v. 25.1","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30,"numEvents":10}],"term":"Eye pruritus"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Ocular adverse events were collected per participant, not per eye.","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v. 25.1","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30,"numEvents":5}],"term":"Eye pain"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Ocular adverse events were collected per participant, not per eye.","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v. 25.1","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":30,"numEvents":9}],"term":"Eye irritation"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Ocular adverse events were collected per participant, not per eye.","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v. 25.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1}],"term":"Lacrimation increased"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Ocular adverse events were collected per participant, not per eye.","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v. 25.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1}],"term":"Ocular discomfort"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v. 25.1","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":30,"numEvents":8}],"term":"Thrombocytopenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v. 25.1","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30,"numEvents":3}],"term":"Neutropenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v. 25.1","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30,"numEvents":3}],"term":"Anemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA v. 25.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":2}],"term":"Abnormal LFT (liver function test)"}],"timeFrame":"Between baseline and earliest death, lost to contact or end of study timeframe, up to 40 months."}